Spero Therapeutics Inc (SPRO) reports a significant revenue decline but advances its lead product candidate, tebipenem HBr, ...

P3 Health Partners Inc (PIII) reports a 7% revenue increase and reaffirms 2025 guidance despite facing elevated medical expenses and EBITDA losses.